The CEBPA gene, a myeloid transcription factor, is mutated in a subset of acute myeloid leukemia (AML), particularly those with chromosome analyses showing normal diploid karyotype, Cytogenetically Normal (CN). CN-AML that have CEBPA mutations show favorable outcome compared to other groups of CN-AML.
Testing for CEBPA mutation, along with NPM1 (test code 16158-NPM (Exon 12) Mutation Analysis, Cell-based) is recommended for all patients with CN-AML.
5.0 mL Whole Blood in a Lavender Top Tube(s) - EDTA
1. 3.0 mL bone marrow collected in a Green Top Tube - Na Heparin
2. Formalin fixed paraffin embedded tissue
Room temperature: Indefinite
Refrigerated: Indefinite
Frozen: See Instructions
Instruction: Don Not Freeze, FFPE is a validated specimen type, however, it is not routinely performed.
3. Cell pellet - This assay is also designed for the remnant cell pellet from Cytogenetics. The cell pellet usually fixed should be transported at room temperature or refrigerated to the laboratory as soon as possible. Please provide a copy of the Cytogenetics report.
7 days Ambient
7 days Refrigerated
2.0 mL
Not detected
The CEBPA gene, a myeloid transcription factor, is mutated in a subset of acute myeloid leukemia (AML), particularly those with chromosome analyses showing normal diploid karyotype, Cytogenetically Normal (CN). CN-AML that have CEBPA mutations show favorable outcome compared to other groups of CN-AML.
Testing for CEBPA mutation, along with NPM1 (test code 16158-NPM (Exon 12) Mutation Analysis, Cell-based) is recommended for all patients with CN-AML.
3 to 6 days
00919218
81218